TetraScience and Snowflake Partner to Accelerate Scientific AI Adoption Across Global Life Sciences

BOSTON–(BUSINESS WIRE)–TetraScience, the Scientific Data and AI Cloud, today announced it is teaming up with Snowflake to enable joint customers to unlock the value of their scientific data and reap the benefits of the Scientific AI revolution. The collaboration will allow the seamless sharing of scientific data between the Tetra Scientific Data and AI Cloud … [Read more…]

Pleno, Inc. Appoints Dr. Vik Vaz, M.D. as Chief Executive Officer & President to Drive Commercial Growth After Closing $25M Series B Funding

Series B Funding from Major Investors Deerfield Management, Foresite Capital and Medical Excellence Capital among others SAN DIEGO–(BUSINESS WIRE)–Pleno, a clinical and multi-omics diagnostics company that is revolutionizing biological target detection, today announced the appointment of Dr. Vik Vaz M.D. as its new chief executive officer and to serve on its Board of Directors, effective … [Read more…]

Owkin unveils new insights into the opportunities and challenges for digital pathology and AI solutions in healthcare

     55% of pathologist and oncologist survey respondents globally are facing stress and burnout due to increasing complexity and high workloads      More than a third highlight burdens they face are detrimental to patient care, and 77% agree that AI will help to cut waiting times for tests, and help with staffing       The … [Read more…]

LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates

Company expects package will not require additional human clinical studies, potentially accelerating path to market LOS ANGELES–(BUSINESS WIRE)–LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company is restarting a process to seek marketing approval of aldoxorubicin under … [Read more…]

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer with ESR1 mutations, aiming to delay disease progression. The study was presented by the Menarini Group and MEDSIR at the San Antonio Breast Cancer Symposium 2024 (SABCS 2024), one of the world’s most prestigious … [Read more…]

RevBio Receives Both FDA Approval to Expand its Clinical Trial and CMS Reimbursement for its Regenerative Bone Adhesive for Cranial Flap Fixation

The Expansion of this Clinical Trial will Broaden the Clinical Use Cases for TETRANITE® and Establish Reimbursement Coverage LOWELL, Mass.–(BUSINESS WIRE)–#BoneRepair–RevBio, Inc., announced that it has received FDA approval to expand its ongoing clinical trial to immediately fixate cranial flaps using TETRANITE®, the company’s bone adhesive biomaterial. The company also received reimbursement coverage from the … [Read more…]

F45 Partners With Magic Johnson Enterprises to Inspire the Next Generation of Fitness Enthusiasts

The Two Powerhouse Organizations Donate More Than 4,000 Fit Kits to Kids in a Joint Effort to Promote Overall Fitness and Well-being AUSTIN, Texas–(BUSINESS WIRE)–F45 Training, a global leader in community-based group fitness, has teamed up with Magic Johnson Enterprises (MJE) – an investment conglomerate founded by world-renowned athlete Earvin “Magic” Johnson – to inspire … [Read more…]

Amidst Declining U.S. Birthrates and Fertility Crisis, New Female-led Startup, Lushi,™ Launches to Transform Options for Women Seeking to Conceive

Lushi debuts in December as 2024 Election Raises Fertility Issues to Forefront of Americans’ Minds Company by Women, For Women will Harness AI To Ease Treatments and Stress of IVF NEW YORK–(BUSINESS WIRE)–With up to a quarter of reproductive-aged women in the U.S. facing fertility challenges and struggling to find treatment from an antiquated and … [Read more…]

Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today the pricing of an upsized underwritten public offering of 13,200,000 shares of its common stock at a public offering price of $12.50 per share. The gross … [Read more…]

Rate of Reporting Sexual Harassment Among UK Doctors Has Tripled, Medscape Survey Reveals

The rate of reporting sexual harassment has tripled among responding doctors since Medscape’s previous research in 2019 (9% versus 3%) Around 3 out of 4 perpetrators (73%) were fellow doctors Most victims (83%) were still required to interact with the perpetrator after the incident LONDON–(BUSINESS WIRE)–Sexual harassment in UK healthcare has reached alarming levels, tripling … [Read more…]